Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...
PUEDES VER:Este alimento que consumes a diario podría producir acné, afirma nutricionista: ¿cuál es y por qué? En el caso de las cápsulas, es preferible tomarlas junto con las comidas para ...
The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...
Aqupi le explicamos para qué sirve tomar café con cúrcuma y cómo ... debemos entender el impacto que cada ingrediente tiene en el organismo. Sobre el primero, una investigación de la ...
This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...
“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...
EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...
Aspectos positivos - Se han reportado resultados positivos de la Fase III para Kisqali y Fabhalta. - Se espera que la presentación de Pluvicto PSMAfore aumente significativamente la población de ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback